For more information on this topic, please refer to the article Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy in the January 2008 issue of Clinical Pharmacology & Therapeutics.

1. What are the limitations of current osteoporosis treatments such as bisphosphonates, estrogens, selective estrogen receptor modulators, and vitamin D derivatives?

2. Considering how human and mouse skeletons differ in terms of estrogen response, is the mouse model adequate for determining bone loss?

3. Is the development of cathepsin K inhibitors crucial for future osteoporosis treatment?